表皮生长因子受体抑制剂(EGFR TKI)在非小细胞肺癌(NSCLC)治疗中发挥了重要的作用,可它的缓解率只有9％～19％,缓解维持时间只有6-8个月,提示存在原发性与获得性耐药。原因包括1．EGFR突变：一般认为EGFR基因20外显子的突变,尤其是T790M再突变与EGFR TKI耐药相关。在我们研究的80例NSCLC患者中,未检测到20外显子突变。在4例应用EGFR TKI治疗缓解后进 Epidermal growth factor receptor inhibitor (EGFR TKI) plays an important role in the treatment of non-small cell lung cancer (NSCLC), but its response rate is only 9% -19% and its maintenance time is only 6-8 months There are primary and acquired resistance. Reasons include 1. EGFR Mutations: Mutations in the exon 20 of the EGFR gene are generally believed to be associated with EGFR TKI resistance, particularly the re-mutation of T790M. In our study of 80 patients with NSCLC, 20 exon mutations were not detected. In 4 cases of EGFR TKI treatment remission